Janeen Noel  Doyle net worth and biography

Janeen Doyle Biography and Net Worth

Insider of Janux Therapeutics

Janeen brings more than 24 years of broad and strategic experience spanning large pharmaceutical companies, mid-sized biotech, and high-growth venture-backed enterprises to her role as Chief Corporate and Business Development Officer at Janux. Prior to joining Janux, Janeen most recently served as a Senior Partner and Senior Vice President of Corporate Partnerships and Program Development at Flagship Pioneering, a life sciences focused venture capital firm. At Flagship, she was responsible for strategy and execution of collaborations between Flagship’s portfolio companies and global pharmaceutical and technology partners. Prior to Flagship, Janeen spent over 15 years at Bristol Myers Squibb and Celgene in a breadth of cross-functional positions of increasing responsibility, starting in areas of medical affairs and program leadership, and most recently serving as Senior Vice President of Strategy & Business Development. In that role, she oversaw a portfolio of 300+ strategic collaborations and a broad equity investing portfolio, including serving as a board observer across investments. Her leadership encompassed partnerships from discovery through commercialization across multiple therapeutic areas. Previous to that, she held roles in clinical science and operations.

Janeen received a Bachelor of Science in biology from Moravian University and a Master of Business Administration from the University of Scranton.

What is Janeen Noel Doyle's net worth?

The estimated net worth of Janeen Noel Doyle is at least $1.01 million as of June 2nd, 2026. Doyle owns 75,941 shares of Janux Therapeutics stock worth more than $1,010,775 as of June 9th. This net worth estimate does not reflect any other investments that Doyle may own. Learn More about Janeen Noel Doyle's net worth.

How do I contact Janeen Noel Doyle?

The corporate mailing address for Doyle and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on Janeen Noel Doyle's contact information.

Has Janeen Noel Doyle been buying or selling shares of Janux Therapeutics?

In the last ninety days, Janeen Noel Doyle has sold $56,947.77 of Janux Therapeutics stock. Most recently, Janeen Noel Doyle sold 4,059 shares of the business's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a transaction totalling $56,947.77. Following the completion of the sale, the insider now directly owns 75,941 shares of the company's stock, valued at $1,065,452.23. Learn More on Janeen Noel Doyle's trading history.

Who are Janux Therapeutics' active insiders?

Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), Thomas Diraimondo (Insider), Maria Dobek (VP), Janeen Doyle (Insider), Zachariah Mciver (Insider), Andrew Meyer (Chief Business Officer), and Charles Winter (Insider). Learn More on Janux Therapeutics' active insiders.

Are insiders buying or selling shares of Janux Therapeutics?

During the last year, insiders at the sold shares 11 times. They sold a total of 48,461 shares worth more than $1,058,011.56. The most recent insider tranaction occured on June, 2nd when insider Janeen Noel Doyle sold 4,059 shares worth more than $56,947.77. Insiders at Janux Therapeutics own 7.9% of the company. Learn More about insider trades at Janux Therapeutics.

Information on this page was last updated on 6/2/2026.

Janeen Noel Doyle Insider Trading History at Janux Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2026Sell4,059$14.03$56,947.7775,941View SEC Filing Icon  
See Full Table

Janeen Noel Doyle Buying and Selling Activity at Janux Therapeutics

This chart shows Janeen Noel Doyle's buying and selling at Janux Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Janux Therapeutics Company Overview

Janux Therapeutics logo
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $13.53
Low: $13.28
High: $13.88

50 Day Range

MA: $14.50
Low: $13.03
High: $15.87

2 Week Range

Now: $13.53
Low: $12.12
High: $35.34

Volume

233,618 shs

Average Volume

1,157,832 shs

Market Capitalization

$825.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53